ReviewMolecular biology reports2026
Lactylation: A central metabolic-epigenetic driver of sepsis-associated acute kidney injury.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Sepsis-associated acute kidney injury is a lethal complication with limited therapeutic options. The discovery of protein lactylation, a novel modification where lactate modifies lysine residues, has redefined lactate from a metabolic waste product to a key epigenetic regulator. This review summarizes the role of lactylation as a central metabolic-epigenetic hub in SA-AKI pathogenesis. We detail its molecular basis, governed by a dynamic "writer-reader-eraser" network. In SA-AKI, lactylation orchestrates a multifaceted pathological cascade: it reprograms immune responses (e.g., altering macrophage polarization), disrupts tubular cell fate (e.g., inducing mitochondrial dysfunction), and compromises microvascular integrity. Its function exhibits cell-type and spatiotemporal specificity, explaining its dual roles in injury and repair. This mechanism provides a new framework for understanding SA-AKI and reveals promising translational avenues: specific lactylation marks (e.g., H3K18 lactylation) are potential diagnostic biomarkers, and targeting this axis offers novel strategies for precision therapy. Overcoming current research challenges is crucial for translating this knowledge into improved patient outcomes.
Indexed as
Identifiers
42658356What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.